JPMorgan Chase & Co. Has $301,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

JPMorgan Chase & Co. lifted its stake in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 141.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 190,457 shares of the biopharmaceutical company's stock after buying an additional 111,485 shares during the period. JPMorgan Chase & Co. owned about 0.29% of Regulus Therapeutics worth $301,000 at the end of the most recent reporting period.

Separately, Barclays PLC boosted its stake in shares of Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 62,549 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Stock Performance

Regulus Therapeutics stock traded down $0.02 during mid-day trading on Tuesday, reaching $7.83. The company's stock had a trading volume of 944,393 shares, compared to its average volume of 872,409. The business's 50 day simple moving average is $2.24 and its 200 day simple moving average is $1.71. Regulus Therapeutics Inc. has a 12 month low of $0.83 and a 12 month high of $8.20. The company has a market capitalization of $518.68 million, a price-to-earnings ratio of -7.32 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). During the same period last year, the company posted ($0.40) earnings per share. As a group, sell-side analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on RGLS shares. Leerink Partnrs cut shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Jones Trading reaffirmed a "hold" rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Leerink Partners reissued a "market perform" rating and set a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Canaccord Genuity Group restated a "hold" rating and issued a $11.00 price target (down from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $8.50.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.